Table 1 Clinical characteristics of MF... | American Society of Hematology

Table 1

Clinical characteristics of MF patients studied

Patient*	Sex	Age, y	Diagnosis	JAK2V617F allele burden, %†	Chromosomal abnormalities (%)*	CALR status	Indication for splenectomy
1	M	65	PMF	0	None	WT	Cytopenias
2	F	70	Post-PV MF	85	None	N/A	Prior to transplant
3	M	74	PMF	0	Unknown	Unknown	Cytopenias
4	F	75	PMF	62	t(3;3)(q21;q26) (73) del(20)(q11.2q13.2) (27)	N/A	Painful splenomegaly
5	M	64	PMF	0	None	WT	Cytopenias
6	M	79	PMF	2.4	del(20)(q11.1q13.3) (97)	WT	Cytopenias
7	M	67	PMF	0	t(8;12)(q13;q15) (100)	46-bp deletion	Cytopenias
8	M	66	PMF	0	None	WT	Prior to transplant
9	F	45	Post-PV MF	90	del(20)(q11.1q13.3) (50)	N/A	Cytopenias
10	F	64	Post-PV MF	78	+der(9)t(1;9)(q12;q12) (35) del(20)(q11.2q13.1) (41)	N/A	Portal hypertension
11	F	58	Post-PV MF	43	del(13)(q12q22) (92)	N/A	Prior to transplant
12	M	73	PMF	85.1	Del(13)(q12q14) (20)	N/A	Palliation of advanced MF

Patient*	Sex	Age, y	Diagnosis	JAK2V617F allele burden, %†	Chromosomal abnormalities (%)*	CALR status	Indication for splenectomy
1	M	65	PMF	0	None	WT	Cytopenias
2	F	70	Post-PV MF	85	None	N/A	Prior to transplant
3	M	74	PMF	0	Unknown	Unknown	Cytopenias
4	F	75	PMF	62	t(3;3)(q21;q26) (73) del(20)(q11.2q13.2) (27)	N/A	Painful splenomegaly
5	M	64	PMF	0	None	WT	Cytopenias
6	M	79	PMF	2.4	del(20)(q11.1q13.3) (97)	WT	Cytopenias
7	M	67	PMF	0	t(8;12)(q13;q15) (100)	46-bp deletion	Cytopenias
8	M	66	PMF	0	None	WT	Prior to transplant
9	F	45	Post-PV MF	90	del(20)(q11.1q13.3) (50)	N/A	Cytopenias
10	F	64	Post-PV MF	78	+der(9)t(1;9)(q12;q12) (35) del(20)(q11.2q13.1) (41)	N/A	Portal hypertension
11	F	58	Post-PV MF	43	del(13)(q12q22) (92)	N/A	Prior to transplant
12	M	73	PMF	85.1	Del(13)(q12q14) (20)	N/A	Palliation of advanced MF

WT, wild-type.

Indicates the percentage of primary MF spleen cells having the given chromosomal abnormality.

Indicates the granulocytic JAK2V617F allele burden as detected by real-time allele specific PCR assay.